Idioma:

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis

Lima, André Bacellar Costa ; Macedo, Ligia T ; Sasse, André Deeke El-Deiry, Wafik S.

PloS one, 2011-08, Vol.6 (8), p.e22681 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis
Autor: Lima, André Bacellar Costa ; Macedo, Ligia T ; Sasse, André Deeke
El-Deiry, Wafik S.
Assuntos: Analysis ; Angiogenesis ; Angiogenesis inhibitors ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Chemotherapy ; Clinical decision making ; Clinical trials ; Confidence intervals ; Cost-benefit analysis ; Decision making ; Drug therapy ; Histology ; Humans ; Hypertension ; Immunotherapy ; Lung cancer ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Lung diseases ; Lung Neoplasms - drug therapy ; Medical prognosis ; Medical research ; Medicine ; Medicine, Experimental ; Meta-analysis ; Metastasis ; Monoclonal antibodies ; Mortality ; Nervous system ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Oncology ; Patients ; Platinum ; Randomized Controlled Trials as Topic ; Small cell lung cancer ; Studies ; Survival ; Survival Analysis ; Systematic review ; Targeted cancer therapy ; Toxicity ; Tumors ; Vascular endothelial growth factor
É parte de: PloS one, 2011-08, Vol.6 (8), p.e22681
Notas: Conceived and designed the experiments: ABL ADS. Performed the experiments: ABL LTM ADS. Analyzed the data: ABL LTM ADS. Contributed reagents/materials/analysis tools: ABL ADS. Wrote the paper: ABL LTM ADS.
Descrição: Recently, studies have demonstrated that the addition of bevacizumab to chemotherapy could be associated with better outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, the benefit seems to be dependent on the drugs used in the chemotherapy regimens. This systematic review evaluated the strength of data on efficacy of the addition of bevacizumab to chemotherapy in advanced NSCLC. PubMed, EMBASE, and Cochrane databases were searched. Eligible studies were randomized clinical trials (RCTs) that evaluated chemotherapy with or without bevacizumab in patients with advanced NSCLC. The outcomes included overall survival (OS), progression-free survival (PFS), response rate (RR), toxicities and treatment related mortality. Hazard ratios (HR) and odds ratios (OR) were used for the meta-analysis and were expressed with 95% confidence intervals (CI). We included results reported from five RCTs, with a total of 2,252 patients included in the primary analysis, all of them using platinum-based chemotherapy regimens. Compared to chemotherapy alone, the addition of bevacizumab to chemotherapy resulted in a significant longer OS (HR 0.89; 95% CI 0.79 to 0.99; p = 0.04), longer PFS (HR 0.73; 95% CI 0.66 to 0.82; p<0.00001) and higher response rates (OR 2.34; 95% CI 1.89 to 2.89; p<0.00001). We found no heterogeneity between trials, in all comparisons. There was a slight increase in toxicities in bevacizumab group, as well as an increased rate of treatment-related mortality. The addition of bevacizumab to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and RR. Considering the toxicities added, and the small absolute benefits found, bevacizumab plus platinum-based chemotherapy can be considered an option in selected patients with advanced NSCLC. However, risks and benefits should be discussed with patients before decision making.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 5 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis

Lima, André Bacellar Costa ; Macedo, Ligia T ; Sasse, André Deeke El-Deiry, Wafik S.

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.